Overview

• Sweden medical technology firm's Q2 net sales rose 34%, beating analyst expectations

• Organic growth reached 36% in local currencies, led by 53% rise in thoracic sales

• Q2 net profit and EPS improved year-over-year, supported by strong sales growth

Outlook

• XVIVO sees significant opportunities for growth across its portfolio and key markets

• Company expects increasing adoption of its technologies to drive future growth

Result Drivers

• THORACIC SALES - Strong growth in thoracic segment, with sales up 53% in local currencies, was the main driver of organic growth, per company

• ABDOMINAL SALES - Abdominal segment sales increased 26% in local currencies, contributing to overall growth

• SERVICES SALES DECLINE - Services sales decreased 25% in local currencies, partially offsetting product sales gains

Company press release: ID:nMFN4mQkS0

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Xvivo Perfusion AB is SEK340.00, about 20.1% above its July 13 closing price of SEK283.00

• The stock recently traded at 55 times the next 12-month earnings vs. a P/E of 56 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.